Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Articles|December 23, 2021
Daily Medication Pearl: Xanax (Alprazolam)
Author(s)Saro Arakelians, PharmD
Xanax is indicated for the acute treatment of generalized anxiety disorder and treatment of panic disorder with or without agoraphobia in adults.
Advertisement
Medication Pearl of the Day: Xanax (Alprazolam)
Indication: Xanax is a benzodiazepine indicated for the acute treatment of generalized anxiety disorder and treatment of panic disorder with or without agoraphobia in adults.
Insight:
- Dosing: The recommended starting oral dosage for Xanax is 0.25 mg to 0.5 mg taken 3 times daily.
- Dosage forms: Xanax tablets come in dosage forms at 0.25 mg, 0.5 mg, 1 mg, and 2 mg.
- Adverse events (AEs): The most common AEs associated with the use of Xanax include impaired coordination, hypotension, dysarthria, and increased libido.
- Mechanism of action: Xanax is a 1,4 benzodiazepine. Xanax exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABAA) receptors in the brain and enhances GABAA-mediated synaptic inhibition.
- Manufacturer: Pfizer
Source:
Advertisement
Related to this article
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
5